In our study of 54 ATTR CA patients who received treatment with the TTR stabilizer tafamidis and underwent baseline, as well as follow-up CMR with T1 mapping, we could detect that an increase in ECV was associated with the composite endpoint of all-cause mortality, cardiac transplantation, or hospitalization due to HF. Here, TTR is linked to hydrops fetalis.